Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Factor X deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Factor X deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Factor X deficiency indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Factor XI deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Factor XI deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Factor XI deficiency strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Factor VII deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Factor VII deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Factor VII deficiency strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Factor V deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Factor V deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Factor V deficiency indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Congenital thrombotic thrombocytopenic purpura Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Congenital thrombotic thrombocytopenic purpura Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Congenital thrombotic thrombocytopenic purpura strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Read →
Gray platelet syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Gray platelet syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Gray platelet syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Bernard-Soulier syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Bernard-Soulier syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Bernard-Soulier syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Glanzmann thrombasthenia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Glanzmann thrombasthenia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Glanzmann thrombasthenia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Cartilage-hair hypoplasia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Cartilage-hair hypoplasia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Cartilage-hair hypoplasia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Schimke immuno-osseous dysplasia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Schimke immuno-osseous dysplasia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Schimke immuno-osseous dysplasia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Ataxia-telangiectasia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Ataxia-telangiectasia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
2026 Ataxia-telangiectasia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Bloom syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Bloom syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
4 August 2026
Explore the 2026 Bloom syndrome indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →